$0.03 Earnings Per Share Expected for OraSure Technologies, Inc. (NASDAQ:OSUR) This Quarter


Share on StockTwits

Brokerages expect OraSure Technologies, Inc. (NASDAQ:OSUR) to announce earnings per share (EPS) of $0.03 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for OraSure Technologies’ earnings, with estimates ranging from $0.01 to $0.05. OraSure Technologies posted earnings of ($0.10) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 130%. The firm is expected to report its next quarterly earnings report on Wednesday, May 5th.

On average, analysts expect that OraSure Technologies will report full year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.04 to $1.73. For the next fiscal year, analysts anticipate that the company will report earnings of $0.80 per share, with EPS estimates ranging from $0.08 to $2.39. Zacks’ earnings per share averages are an average based on a survey of research firms that follow OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Monday, March 1st. The medical instruments supplier reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). The company had revenue of $62.90 million for the quarter, compared to analyst estimates of $57.30 million. OraSure Technologies had a negative net margin of 9.05% and a negative return on equity of 3.51%. The firm’s revenue for the quarter was up 26.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 earnings per share.

Several research analysts have recently commented on the company. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 3rd. Citigroup reduced their target price on OraSure Technologies from $18.00 to $16.00 in a report on Tuesday, March 2nd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $16.71.

NASDAQ OSUR traded down $0.13 during trading on Friday, reaching $10.32. 4,059 shares of the company traded hands, compared to its average volume of 1,126,327. The company has a market cap of $742.48 million, a price-to-earnings ratio of -45.43 and a beta of 0.04. OraSure Technologies has a 1-year low of $9.46 and a 1-year high of $19.75. The stock’s 50 day moving average price is $11.11 and its two-hundred day moving average price is $12.57.

A number of large investors have recently bought and sold shares of the business. 6 Meridian lifted its holdings in OraSure Technologies by 5.9% during the 4th quarter. 6 Meridian now owns 22,977 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 1,285 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in OraSure Technologies by 5.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 42,347 shares of the medical instruments supplier’s stock worth $448,000 after buying an additional 2,039 shares in the last quarter. AdvisorNet Financial Inc acquired a new position in OraSure Technologies during the 4th quarter worth $26,000. The Manufacturers Life Insurance Company lifted its holdings in OraSure Technologies by 7.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 40,308 shares of the medical instruments supplier’s stock worth $491,000 after buying an additional 2,902 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of OraSure Technologies by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 469,824 shares of the medical instruments supplier’s stock valued at $4,974,000 after acquiring an additional 2,950 shares during the last quarter. 98.13% of the stock is currently owned by hedge funds and other institutional investors.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Article: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.